SARS-CoV-2-IgM/IgG-Test-Kit(Immunochromatographic-Assay) |
EGIVD008 |
EnoGene |
CE-recogniton-IVD |
EUR 350 |
Description: CE recogniton IVD |
Human IgG antibody Laboratories manufactures the sars cov 1 antibody test results reagents distributed by Genprice. The Sars Cov 1 Antibody Test Results reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Antibody. Other Sars products are available in stock. Specificity: Sars Category: Cov Group: 1 Antibody
HPV (Human Papilloma Virus Antibody IgG) ELISA test |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of HPV (Human Papilloma Virus Antibody IgG) |
MV (Measles Virus Antibody IgG) ELISA test |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of MV (Measles Virus Antibody IgG) |
TB (Mycobacterium Tuberculosis Antibody IgG) ELISA test |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of TB (Mycobacterium Tuberculosis Antibody IgG) |
MP (Mycoplasma Pneumoniae Antibody IgG) ELISA test |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of MP (Mycoplasma Pneumoniae Antibody IgG) |
Cpn (Chlamydia Pneumoniae Antibody IgG) ELISA test |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of Cpn (Chlamydia Pneumoniae Antibody IgG) |
AOA (Anti-ovary Antibody IgG) ELISA test |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of AOA (Anti-ovary Antibody IgG) |
EM (Anti-endometrial Antibody IgG) ELISA test |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of EM (Anti-endometrial Antibody IgG) |
1 Antibody information
TruStrip RDT Zaire Ebola Virus antigen (GP) rapid test (visual results in 2-10 mins), 10 cassettes/pk |
AE-320805-RDT-10 |
Alpha Diagnostics |
1 pk |
EUR 343.2 |
TruStrip RDT Beta-Lactam and Tetracyclines rapid test strips, results is 2-10 mins, 50 strips/pk |
DE-100260-RDT |
Alpha Diagnostics |
1 pk |
Ask for price |
TruStrip RDT Canine distemper virus (hardpad disease) antigen rapid test card, results is 2-10 mins, 50 cards/pk |
RV-501200-RDT |
Alpha Diagnostics |
1 pk |
Ask for price |
TruStrip RDT Humanized Ebola IgG (humanized IgGs expressed in tobacco or other plants) rapid test (results in 2-10 min), 25 cassettes/pk |
AE-320880-RDT-25 |
Alpha Diagnostics |
1 pk |
EUR 351.6 |
SARS-CoV-2 Antigen Rapid Test Kit |
CoV2Ag-1 |
UnScience |
1T |
EUR 9.6 |
|
Description: This kit adopts the sandwich method and the technical principle of colloidal gold immunochromatography to qualitative determine the SARS-CoV-2 antigen. During the test, the sample is dropped into the sample well, and chromatography is performed under the capillary effect. The SARS-CoV-2 antigen in the sample combined with the colloidal goldlabeled SARS-CoV-2 monoclonal antibody I, and then spread to the test area. It is captured by another coated antibody (SARS-CoV-2 monoclonal antibody II), to form a complex and gather in the test area (T line). The quality control area is coated with the goat antimouse antibody, and the colloidal gold-labeled antibody is captured to form a complex and aggregate in the quality control area (C line). If the C line does not show color, it indicates that the result is invalid, and this sample needs to be tested again. |
SARS-CoV-2 Antigen Rapid Test Kit |
CoV2Ag-25 |
UnScience |
25T/kit |
EUR 42 |
|
Description: This product is used for in vitro qualitative detection of SARS-CoV-2 antigen in human oropharyngeal swabs, nasal swabs and nasopharyngeal swabs. It is helpful as an aid in the screening of early mild, asymptomatic, or acute patients for identification of SARS-CoV-2 infection. |
SARS-CoV-2 Rapid Antigen Test Nasal |
9901-NCOV-03G |
Roche Diagnostics |
25 Tests/Kit |
EUR 112.8 |
|
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke |
Avacta AffiDX SARS-CoV-2 Antigen Lateral Flow Test |
BSV-COV-11711125 |
BioServUK |
25 tests |
Ask for price |
Description: Avacta AffiDX SARS-CoV-2 Antigen Lateral Flow Test |
SARS-CoV/ SARS-CoV-2 (COVID-19) spike antibody [1A9] |
BSV-COV-AB-01 |
BioServUK |
25 ul |
Ask for price |
Description: SARS-CoV/ SARS-CoV-2 (COVID-19) spike antibody [1A9] (Spike (S2), Monoclonal) |
Lysis Buffer for SARS-CoV-2 Antigen Test Development |
LY-14 |
ACROBIOSYSTEMS |
10ml |
EUR 973.7 |
|
Description: N/A |
anti- SARS antibody |
FNab07609 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against SARS |
Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (Saliva) |
IOV87952 |
INVBIO |
20T/kit |
EUR 46.8 |
Description: Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (Saliva) is an in vitro diagnostic test for the qualitative detection of novel coronavirus antigens in human saliva, using the rapid immunochromatographic method. The identification is based on the monoclonal antibodies specific for the novel coronvirus antigen. It will provide information for clinical doctors to prescribe correct medications. |
SARS-CoV/ SARS-CoV-2 (COVID-19) spike antibody [1A9] 100 ul |
BSV-COV-AB-02 |
BioServUK |
100 ul |
Ask for price |
Description: SARS-CoV/ SARS-CoV-2 (COVID-19) spike antibody [1A9] (Spike (S2), Monoclonal) |
GENLISA™ SARS-CoV-2 (Covid-19) Surrogate Virus Neutralization Test (sVNT) ELISA |
KBVH400 |
Krishgen |
12 × 8 wells |
EUR 3822 |
SARS-CoV-2 (COVID-19) NSP7 Antibody |
9155-002mg |
ProSci |
0.02 mg |
EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP7 plays a role in viral RNA synthesis (3,4,5). It forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers. |
SARS-CoV-2 (COVID-19) NSP7 Antibody |
9155-01mg |
ProSci |
0.1 mg |
EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP7 plays a role in viral RNA synthesis (3,4,5). It forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers. |
SARS-CoV-2 (COVID-19) NSP8 Antibody |
9159-002mg |
ProSci |
0.02 mg |
EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP8 plays a role in viral RNA synthesis (3,4,5). Forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers (6). |